We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Pushes Back Review of Biogen and Eisai’s Alzheimer’s Drug by Three Months
FDA Pushes Back Review of Biogen and Eisai’s Alzheimer’s Drug by Three Months
The FDA has delayed its review of Biogen and Eisai’s highly anticipated Alzheimer’s treatment candidate aducanumab, pushing back its action date to June 7 after deciding it needs more time to review additional analyses and clinical data from the drugmakers.